PharmaSGP is a German consumer health company that develops and markets over-the-counter pharmaceuticals and healthcare products built on natural active ingredients. Its focus is on systemic chemical-free pain remedies and natural sleep aids, categories in which it holds the market-leading position in Germany. The company introduced its first product in Germany in 2012 and reports revenue of €101.1 million for 2023, alongside an adjusted EBITDA margin of 33.7%.
The portfolio is built around three flagship brands. RubaXX® treats rheumatic pain, Restaxil® addresses neuralgic and nerve pain, and Baldriparan® serves as a natural sleep aid; each holds a category-leading position in the German market. PharmaSGP continues to expand this portfolio with individually tailored solutions, and sells across Europe, with presence in Germany, Austria, Italy, Belgium, Spain and France.
Internally, the company emphasises strong customer orientation and very high quality standards, alongside a stated focus on patient wellbeing, innovation and sustainable growth. It describes its operating belief as one in which exceptional healthcare products come from dedicated teams with real ownership of their mission, and frames its purpose as improving patients' quality of life.
